{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T05:44:34Z","timestamp":1793684674834,"version":"4.5.1"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"\n Importance<\/jats:title>\n Immune checkpoint inhibitors (ICIs) have transformed cancer outcomes but may be associated with an increased risk of myocardial infarction and ischemic stroke. Whether this risk is mediated by inflammatory plaque activation and whether coadministered vascular endothelial growth factor inhibitors (VEGFIs) modify the effect remain unresolved.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To prospectively characterize the arterial and systemic inflammatory outcomes associated with ICIs, VEGFIs, and combined ICIs plus VEGFIs in patients with cancer.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This prospective longitudinal cohort study was conducted between August 2022 and June 2024 at the West of Scotland regional cancer hospital network. Adults with cancer who were planned to receive ICI monotherapy, VEGFI monotherapy, or combined ICI plus VEGFI therapy underwent imaging and venous blood sampling at baseline (before treatment) and at 24 weeks. Data were analyzed from June 2024 to October 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n \n Undergoing (\n 18<\/jats:sup>\n F)fluorodeoxyglucose positron emission tomography computed tomography ([\n 18<\/jats:sup>\n F]FDG-PET\/CT) imaging.\n <\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n \n Arterial inflammation was quantified by (\n 18<\/jats:sup>\n F)FDG-PET\/CT using imaging protocols optimized for vascular assessment. The primary outcome was the between-group difference in change in maximal tissue to background ratio (TBRmax) over time, evaluated by analysis of covariance adjusted for baseline. Systemic inflammatory biomarkers were measured by enzyme-linked immunosorbent assay and a proteomic panel. Circulating immune cell phenotypes were profiled using spectral flow cytometry.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 55 evaluable patients (mean [SD] age, 66 [10] years; 39 male [71%] and 16 female [29%]), 20 received ICIs, 15 received VEGFIs, and 20 received ICIs plus VEGFIs. At 24 weeks, TBRmax did not exceed baseline in any group (ICIs: mean [SD], 1.71 [0.14] vs 1.67 [0.14]; VEGFIs: mean [SD], 1.72 [0.22] vs 1.72 [0.17]; ICIs + VEGFIs: mean [SD], 1.74 [0.18] vs 1.64 [0.15]; among groups:\n P<\/jats:italic>\n \u2009=\u2009.13). Findings were consistent across artery type, calcification status, prior atherosclerotic disease, and steroid exposure. ICI therapy was associated with selectively altered T-cell subsets, an outcome attenuated by concurrent VEGFI therapy, while VEGFI therapy alone had no significant association with circulating immune cells. Across all 3 regimens, systemic inflammatory biomarkers showed only modest changes. Intracellular adhesion molecule-1 and vascular cell adhesion molecule-1 increased in patients exposed to ICIs.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n \n In this prospective cohort study, ICIs and VEGFIs, alone and in combination, were not associated with (\n 18<\/jats:sup>\n F)FDG-PET\/CT\u2013detectable arterial inflammation, and systemic inflammatory outcomes were limited. These findings argue against macrophage-driven plaque activation as a primary mechanism of ICI-associated atherothrombosis and support prioritization of endothelial and thrombotic pathways in future mechanistic and preventive studies.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamacardio.2026.3443","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:00:27Z","timestamp":1788966027000},"page":"991","source":"Crossref","is-referenced-by-count":1,"title":["PET, Proteomics, and Immunophenotyping of Arterial Inflammation and Checkpoint Inhibition"],"prefix":"10.1001","volume":"11","author":[{"given":"Stephen","family":"Rankin","sequence":"first","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"MacRitchie","sequence":"additional","affiliation":[{"name":"School of Infection & Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moustafa I.","family":"Morsy","sequence":"additional","affiliation":[{"name":"School of Infection & Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair J.","family":"Gemmell","sequence":"additional","affiliation":[{"name":"Department of Clinical Physics & Bioengineering, NHS Greater Glasgow & Clyde, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alasdair","family":"Henderson","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Glen","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katriona","family":"Brooksbank","sequence":"additional","affiliation":[{"name":"NHS Greater Glasgow & Clyde, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Slomka","sequence":"additional","affiliation":[{"name":"Cedars-Sinai, Division of Artificial Intelligence in Medicine, Department of Medicine, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran F.","family":"Docherty","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc R.","family":"Dweck","sequence":"additional","affiliation":[{"name":"University of Edinburgh, Edinburgh, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"McClure","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Butler","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Welsh","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Slater","sequence":"additional","affiliation":[{"name":"The Beatson, West of Scotland Cancer Centre, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manreet","family":"Randhawa","sequence":"additional","affiliation":[{"name":"The Beatson, West of Scotland Cancer Centre, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashita","family":"Waterston","sequence":"additional","affiliation":[{"name":"The Beatson, West of Scotland Cancer Centre, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Yang","sequence":"additional","affiliation":[{"name":"School of Infection & Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Alsaeed","sequence":"additional","affiliation":[{"name":"School of Infection & Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavlina","family":"Spiliopoulou","sequence":"additional","affiliation":[{"name":"The Beatson, West of Scotland Cancer Centre, Glasgow, United Kingdom"},{"name":"School of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Jones","sequence":"additional","affiliation":[{"name":"The Beatson, West of Scotland Cancer Centre, Glasgow, United Kingdom"},{"name":"School of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Naylor","sequence":"additional","affiliation":[{"name":"The Beatson, West of Scotland Cancer Centre, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R. Jeffry","family":"Evans","sequence":"additional","affiliation":[{"name":"The Beatson, West of Scotland Cancer Centre, Glasgow, United Kingdom"},{"name":"School of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balaji","family":"Venugopal","sequence":"additional","affiliation":[{"name":"The Beatson, West of Scotland Cancer Centre, Glasgow, United Kingdom"},{"name":"School of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Small","sequence":"additional","affiliation":[{"name":"Department of Clinical Physics & Bioengineering, NHS Greater Glasgow & Clyde, Glasgow, United Kingdom"},{"name":"School of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Colville","sequence":"additional","affiliation":[{"name":"University of Edinburgh, Edinburgh, United Kingdom"},{"name":"School of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Petrie","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Maffia","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom"},{"name":"School of Infection & Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom"},{"name":"Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Naples, Italy"},{"name":"Africa-Europe CoRE in Non-Communicable Diseases & Multimorbidity, African Research Universities Alliance & The Guild of European Research-intensive Universities, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninian N.","family":"Lang","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"hoi260046r1","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1001\/jamaoncol.2019.2187","article-title":"Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab.","volume":"5","author":"Topalian","year":"2019","journal-title":"JAMA Oncol"},{"issue":"8","key":"hoi260046r2","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma.","volume":"385","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"hoi260046r3","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.jaccao.2022.11.011","article-title":"Atherosclerosis with immune checkpoint inhibitor therapy: evidence, diagnosis, and management: JACC: CardioOncology state-of-the-art review.","volume":"4","author":"Suero-Abreu","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"24","key":"hoi260046r4","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque.","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"issue":"4","key":"hoi260046r5","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1007\/s00259-015-3259-3","article-title":"Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM) on PET imaging of atherosclerosis.","volume":"43","author":"Bucerius","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"24","key":"hoi260046r6","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1161\/CIRCULATIONAHA.120.048708","article-title":"Immune checkpoint inhibitor therapy induces inflammatory activity in large arteries.","volume":"142","author":"Calabretta","year":"2020","journal-title":"Circulation"},{"issue":"11","key":"hoi260046r7","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.3390\/biology10111206","article-title":"Immune checkpoint inhibitor therapy induces inflammatory activity in the large arteries of lymphoma patients under 50 years of age.","volume":"10","author":"Calabretta","year":"2021","journal-title":"Biology (Basel)"},{"issue":"1","key":"hoi260046r8","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3390\/life14010146","article-title":"Induction of arterial inflammation by immune checkpoint inhibitor therapy in lung cancer patients as measured by 2-[18F]FDG positron emission tomography\/computed tomography depends on pre-existing vascular inflammation.","volume":"14","author":"Calabretta","year":"2024","journal-title":"Life (Basel)"},{"issue":"4","key":"hoi260046r9","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.jaccao.2020.08.007","article-title":"Immune checkpoint inhibitor therapy aggravates T cell\u2013driven plaque inflammation in atherosclerosis.","volume":"2","author":"Poels","year":"2020","journal-title":"JACC CardioOncol"},{"issue":"2","key":"hoi260046r10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.124.016851","article-title":"Longitudinal assessment of subclinical arterial inflammation in patients receiving immune checkpoint inhibitors by sequential [18F]FDG PET scans.","volume":"18","author":"Bacmeister","year":"2025","journal-title":"Circ Cardiovasc Imaging"},{"key":"hoi260046r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2024.118595","article-title":"Arterial inflammation on [18F]FDG PET\/CT in melanoma patients treated with and without immune checkpoint inhibitors: CHECK-FLAME I.","volume":"398","author":"Polomski","year":"2024","journal-title":"Atherosclerosis"},{"issue":"8","key":"hoi260046r12","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-021-00496-y","article-title":"Anti-angiogenic agents\u2014overcoming tumour endothelial cell anergy and improving immunotherapy outcomes.","volume":"18","author":"Huinen","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"hoi260046r13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1042\/CS20241529","article-title":"Arterial effects of anthracycline: structural and inflammatory assessments in non-human primates and lymphoma patients.","volume":"139","author":"Rankin","year":"2025","journal-title":"Clin Sci (Lond)"},{"issue":"4","key":"hoi260046r14","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/0735-1097(90)90282-T","article-title":"Quantification of coronary artery calcium using ultrafast computed tomography.","volume":"15","author":"Agatston","year":"1990","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"hoi260046r15","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.jacc.2013.04.066","article-title":"Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography\/computed tomography feasibility study.","volume":"62","author":"Tawakol","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"hoi260046r16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jacc.2013.07.050","article-title":"Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A2 inhibitor, on arterial inflammation as assessed with 18F-fluorodeoxyglucose-positron emission tomography imaging.","volume":"63","author":"Tawakol","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"hoi260046r17","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1093\/eurheartj\/ehaa884","article-title":"The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study.","volume":"42","author":"D\u2019Souza","year":"2021","journal-title":"Eur Heart J"},{"issue":"29","key":"hoi260046r18","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1200\/JCO.21.01808","article-title":"Incidence of cardiovascular events in patients treated with immune checkpoint inhibitors.","volume":"40","author":"Laenens","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"hoi260046r19","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jaccao.2019.11.013","article-title":"Immune checkpoint inhibitor-related adverse cardiovascular events in patients with lung cancer.","volume":"1","author":"Chitturi","year":"2019","journal-title":"JACC CardioOncol"},{"key":"hoi260046r20","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.21037\/tlcr.2017.12.10","article-title":"Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis.","volume":"6","author":"Hu","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"hoi260046r21","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ejca.2021.01.043","article-title":"Cardiotoxicity of immune checkpoint inhibitors: a systematic review and meta-analysis of randomised clinical trials.","volume":"148","author":"Agostinetto","year":"2021","journal-title":"Eur J Cancer"},{"key":"hoi260046r22","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1309100","article-title":"Risk of cardiovascular toxicity with combination of immune-checkpoint inhibitors and angiogenesis inhibitors: a meta-analysis.","volume":"11","author":"Inno","year":"2024","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"hoi260046r23","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jaccao.2023.12.010","article-title":"Cardiovascular Eligibility Criteria and Adverse Event Reporting in Combined Immune Checkpoint and VEGF Inhibitor Trials.","volume":"6","author":"Rankin","year":"2024","journal-title":"JACC CardioOncol"},{"issue":"4","key":"hoi260046r24","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jcmg.2010.01.004","article-title":"Feasibility of FDG imaging of the coronary arteries: comparison between acute coronary syndrome and stable angina.","volume":"3","author":"Rogers","year":"2010","journal-title":"JACC Cardiovasc Imaging"},{"issue":"13","key":"hoi260046r25","doi-asserted-by":"publisher","first-page":"5060","DOI":"10.1007\/s00259-025-07345-5","article-title":"Image reconstruction and analysis of atherosclerosis imaging by [18F]FDG PETCT using digital PET technology.","volume":"52","author":"Rankin","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"hoi260046r26","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1097\/MNM.0000000000001468","article-title":"Compared to conventional PET\/CT scanners, silicon-photomultiplier-based PET\/CT scanners show higher arterial 18F-FDG uptake in whole-body 18F-FDG-PET\/CT.","volume":"42","author":"Kaneko","year":"2021","journal-title":"Nucl Med Commun"},{"issue":"4","key":"hoi260046r27","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000247","article-title":"Cardiotoxicity of immune checkpoint inhibitors.","volume":"2","author":"Varricchi","year":"2017","journal-title":"ESMO Open"},{"issue":"1","key":"hoi260046r28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.immuni.2013.07.005","article-title":"Deciphering and reversing tumor immune suppression.","volume":"39","author":"Motz","year":"2013","journal-title":"Immunity"},{"issue":"17","key":"hoi260046r29","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202204378","article-title":"Intracellular adhesion molecule-1 improves responsiveness to immune checkpoint inhibitor by activating CD8+ T cells.","volume":"10","author":"Lee","year":"2023","journal-title":"Adv Sci (Weinh)"},{"issue":"9","key":"hoi260046r30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2021.166170","article-title":"VCAM-1 as a predictor biomarker in cardiovascular disease.","volume":"1867","author":"Troncoso","year":"2021","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"10","key":"hoi260046r31","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.24685","article-title":"Serum VCAM-1 and ICAM-1 measurement assists for MACE risk estimation in ST-segment elevation myocardial infarction patients.","volume":"36","author":"Yu","year":"2022","journal-title":"J Clin Lab Anal"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2853940\/jamacardiology_rankin_2026_oi_260046_1790870200.52403.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:00:51Z","timestamp":1791990051000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2853940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2026.3443","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}